盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688373 盟科药业

交易中 07-25 14:19:01

{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业","latestPrice":7.67,"timestamp":1753424341000,"preClose":7.72,"halted":0,"volume":12657062,"delay":0,"changeRate":-0.0065,"floatShares":366000000,"shares":656000000,"eps":-0.6105,"marketStatus":"交易中","change":-0.05,"latestTime":"07-25 14:19:01","open":7.78,"high":7.79,"low":7.54,"amount":96989700,"amplitude":0.0324,"askPrice":7.68,"askSize":100,"bidPrice":7.67,"bidSize":129,"shortable":0,"etf":0,"ttmEps":-0.6105,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753426800000},"marketStatusCode":2,"adr":0,"adjPreClose":7.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":8.49,"lowLimit":6.95,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":655605491,"isCdr":false,"pbRate":13.17,"roa":"--","roe":"--","epsLYR":-0.67,"committee":0.156543,"marketValue":5028000000,"turnoverRate":0.0346,"status":1,"floatMarketCap":2808000000},"requestUrl":"/m/hq/s/688373","defaultTab":"news","newsList":[{"id":"2553235228","title":"盟科药业：公司目前在财务类指标不存在被纳入ST或退市风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2553235228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553235228?lang=zh_cn&edition=full","pubTime":"2025-07-22 16:45","pubTimestamp":1753173955,"startTime":"0","endTime":"0","summary":"证券之星消息，盟科药业(688373)07月22日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司连续多年亏损，营收小于3亿，快ST了？盟科药业回复：尊敬的投资者朋友您好！公司是按照科创板第五套上市的企业，第五套上市企业的相关退市财务指标自上市之日起第4个完整会计年度起适用。根据现行《上海证券交易所科创板股票上市规则》等相关规定，公司目前在财务类指标不存在被纳入“实施其他风险警示（ST）”或退市风险。感谢对我们公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200026562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2553265144","title":"盟科药业深度报告：聚焦创新抗菌 开拓感染治疗新蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2553265144","media":"中泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553265144?lang=zh_cn&edition=full","pubTime":"2025-07-21 00:00","pubTimestamp":1753027200,"startTime":"0","endTime":"0","summary":"医院覆盖数量增加到582 家，正式准入及批量临采医院达150 家，这有助于产品的市场渗透。MRX-4/康替唑胺片全球III 期临床正在稳步开展，治疗糖尿病足感染与皮肤感染。此外，公司的MRX-8/MRX-5 也均在海外完成临床I 期，安全性良好，且MRX-5 在25 年获得FDA 孤儿药资格认定，后续有望快速推进临床与上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721143122a4589f67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721143122a4589f67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2552437109","title":"盟科药业股东大会通过补选董事议案，吴潘成、张怀颖当选","url":"https://stock-news.laohu8.com/highlight/detail?id=2552437109","media":"中访网数据","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552437109?lang=zh_cn&edition=full","pubTime":"2025-07-18 08:03","pubTimestamp":1752797018,"startTime":"0","endTime":"0","summary":"中访网数据  上海盟科药业股份有限公司于2025年7月17日召开2025年第一次临时股东大会，审议通过了补选公司第二届董事会董事的议案。在独立董事选举中，张怀颖女士以191,701,365票当选，而蒋德权先生因得票率未达要求未能当选。上海市方达律师事务所对本次股东大会进行了见证，并出具了法律意见书，认为会议的召集、召开及表决程序符合相关法律法规和公司章程的规定。此次董事补选将进一步完善盟科药业公司治理结构，为公司未来发展提供支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071808143497aa65b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071808143497aa65b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2552172219","title":"盟科药业-U涨5.21% 创年内新高69.51% 资金博弈与研发进展共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2552172219","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552172219?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:45","pubTimestamp":1752720359,"startTime":"0","endTime":"0","summary":"盟科药业-U股价大幅上涨，最新价7.88元，涨跌幅为5.21%。资金动能与市场情绪共振盟科药业-U近期净流入与资金面高频波动密切相关。截至7月14日，该股近一个月主力资金多次出现超500万元级别单日净流入或流出，7月16日单日净流入达1385.9万元，显示市场情绪快速切换。截至7月17日，股价较年初上涨59.51%，后市需业绩放量验证成长逻辑，投资者需关注商业化节奏与研发风险间的平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717104610a44ff00e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717104610a44ff00e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688327","688343","688221","688322","688176","688382","688192","688302","01877","688373","06160","688197","02402","688220","688316","688266","688702","688512","BK0239","688165","000690.SH","688280","688538","09969","688549","688515","688277","688561","688256","688469","ONC","688443","688387"],"gpt_icon":0},{"id":"2551164781","title":"盟科药业-U股价微跌0.40% 创新药企研发管线引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164781","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551164781?lang=zh_cn&edition=full","pubTime":"2025-07-15 19:48","pubTimestamp":1752580100,"startTime":"0","endTime":"0","summary":"盟科药业-U股价报7.40元，较前一交易日下跌0.03元。盘中波动区间为7.21元至7.41元，成交金额达1.09亿元。该公司属于生物医药行业，专注于抗感染创新药物的研发与商业化。作为一家创新型生物制药企业，盟科药业-U主要研发针对耐药菌感染的抗菌新药。从资金流向来看，当日主力资金净流出756.59万元，占流通市值的0.28%。该股当前市盈率为-19.68，显示公司仍处于研发投入阶段。风险提示：以上信息仅供参考，不构成任何投资建议。医药研发存在较大不确定性，投资者需审慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071519533295436bf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071519533295436bf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688373","BK0239"],"gpt_icon":0},{"id":"2550619798","title":"盟科药业-U涨5.13% 医药板块轮动引资金博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=2550619798","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550619798?lang=zh_cn&edition=full","pubTime":"2025-07-10 14:41","pubTimestamp":1752129710,"startTime":"0","endTime":"0","summary":"盟科药业-U今日股价表现强劲，截至14点41分，最新价为7.17元/股，涨幅达5.13%。资金博弈与市场情绪共振盟科药业-U近期净流入与主力资金高频流动密切相关。板块轮动是核心诱因，6月下旬医药板块因防御属性吸引资金流入，但随着7月市场风格切换，化学制药行业资金出现结构性流出压力。研发转化与商业化进程定调价值中枢作为创新药企，盟科药业-U的长期价值取决于核心产品康替唑胺片的商业化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710144157a6a0ef44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710144157a6a0ef44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688373","BK0239"],"gpt_icon":0},{"id":"2549158253","title":"盟科药业公布国际专利申请：“硼化合物前药的盐型、晶型及其药物组合物和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2549158253","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549158253?lang=zh_cn&edition=full","pubTime":"2025-07-05 05:06","pubTimestamp":1751663209,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示盟科药业（688373）公布了一项国际专利申请，专利名为“硼化合物前药的盐型、晶型及其药物组合物和用途”，专利申请号为PCT/CN2024/142599，国际公布日为2025年7月3日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来盟科药业已公布的国际专利申请1个。结合公司2024年年报财务数据，2024年公司在研发方面投入了3.69亿元，同比增6.87%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070500005143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2548360038","title":"上海盟科药业提名蒋德权为第二届董事会独立董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2548360038","media":"中访网数据","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548360038?lang=zh_cn&edition=full","pubTime":"2025-07-02 08:10","pubTimestamp":1751415013,"startTime":"0","endTime":"0","summary":"中访网数据  上海盟科药业股份有限公司近日宣布，提名蒋德权为公司第二届董事会独立董事候选人。蒋德权已通过公司提名委员会的资格审查，并签署独立董事候选人声明与承诺，确认其具备独立董事任职资格及独立性。蒋德权承诺，在任职期间将严格遵守法律法规及监管要求，确保履职的独立性和有效性。盟科药业此次独立董事提名，旨在进一步完善公司治理结构，强化董事会独立性，符合监管机构对上市公司规范运作的要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070208131995332e18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070208131995332e18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2548100446","title":"盟科药业：非独立董事吉冬梅辞职，提名吴潘成补选，独立董事黄寒梅辞职，提名张怀颖和蒋德权补选","url":"https://stock-news.laohu8.com/highlight/detail?id=2548100446","media":"公司公告","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548100446?lang=zh_cn&edition=full","pubTime":"2025-07-01 21:05","pubTimestamp":1751375122,"startTime":"0","endTime":"0","summary":"盟科药业公告，非独立董事吉冬梅因任职单位内部调整辞职，提名吴潘成补选为非独立董事；独立董事黄寒梅因个人原因辞职，提名张怀颖和蒋德权为独立董事候选人。上述补选需经股东大会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701210902a4c90f27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701210902a4c90f27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2548502447","title":"盟科药业股价涨5.10% 医保优化或促价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2548502447","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548502447?lang=zh_cn&edition=full","pubTime":"2025-07-01 13:27","pubTimestamp":1751347632,"startTime":"0","endTime":"0","summary":"盟科药业-U今日股价大幅上涨，截至13点26分，最新价为6.59元/股，涨幅达5.10%。资金博弈与板块轮动共振盟科药业-U近期股价波动与资金面变化紧密相关。技术面上，该股6月26日触及6.27元高点后回落，部分资金选择在阻力位兑现收益，当日振幅达4.09%，反映多空分歧加剧。随着医保谈判规则优化，具备技术壁垒的创新药企有望迎来价值重估，但需警惕研发进度不及预期的市场情绪波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701132724a4c82846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701132724a4c82846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2547701629","title":"每周股票复盘：盟科药业（688373）2024年营收1.30亿元，净亏损4.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2547701629","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547701629?lang=zh_cn&edition=full","pubTime":"2025-06-29 06:18","pubTimestamp":1751149097,"startTime":"0","endTime":"0","summary":"截至2025年6月27日收盘，盟科药业报收于6.18元，较上周的6.06元上涨1.98%。本周，盟科药业6月24日盘中最高价报6.4元。主要内容包括：1）研发支出方面，2024年公司实现营业收入1.30亿元，归母净亏损4.41亿元，全年研发投入3.69亿元，其中委托研发费用2.73亿元，重点推进MRX-4在糖尿病足感染适应症上的全球多中心临床III期试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062900001143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"gpt_icon":0},{"id":"2546715514","title":"盟科药业：关于2024年研发支出及MRX-4临床试验进展的说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2546715514","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546715514?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:48","pubTimestamp":1751014106,"startTime":"0","endTime":"0","summary":"盟科药业公告，公司2024年研发投入3.69亿元，其中MRX-4项目投入2.47亿元，主要用于糖尿病足感染适应症的全球多中心III期临床试验。公司预计MRX-4在美国市场的潜在规模在ABSSSI和DFI适应症上分别为2.8亿美元和6.4亿美元，并重点推进其商业化潜力。同时，公司披露了近三年委托研发费用与研发进展的匹配性分析。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627170446a7207a1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627170446a7207a1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2546034783","title":"盟科药业-U06月26日主力净流出721.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2546034783","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546034783?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922484,"startTime":"0","endTime":"0","summary":"06月26日, 盟科药业-U股价跌3.30%，报收6.15元，成交金额6940.8万元，换手率3.07%，振幅4.09%，量比1.15。盟科药业-U今日主力资金净流出721.9万元，上一交易日主力净流入191.4万元。该股近5个交易日上涨0.65%，主力资金累计净流出711.4万元；近20日主力资金累计净流出4500.4万元，其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171026a71e93e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171026a71e93e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2545340489","title":"盟科药业-U06月24日获主力加仓87.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545340489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545340489?lang=zh_cn&edition=full","pubTime":"2025-06-24 15:20","pubTimestamp":1750749640,"startTime":"0","endTime":"0","summary":"06月24日, 盟科药业-U股价涨0.48%，报收6.33元，成交金额6145.9万元，换手率2.65%，振幅1.90%，量比0.83。盟科药业-U今日主力资金净流入87.0万元，上一交易日主力净流入38.1万元。该股近5个交易日下跌0.78%，主力资金累计净流出1169.1万元；近20日主力资金累计净流出5103.0万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624165209a71ae42d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624165209a71ae42d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2545914104","title":"盟科药业-U06月23日主力净流入38.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2545914104","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545914104?lang=zh_cn&edition=full","pubTime":"2025-06-23 15:20","pubTimestamp":1750663222,"startTime":"0","endTime":"0","summary":"06月23日, 盟科药业-U股价涨3.96%，报收6.30元，成交金额7198.2万元，换手率3.18%，振幅5.94%，量比0.96。盟科药业-U今日主力资金净流入38.1万元，上一交易日主力净流出306.1万元。该股近5个交易日下跌6.25%，主力资金累计净流出2915.8万元；近20日主力资金累计净流出7394.4万元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623164929a71860ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623164929a71860ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2544142970","title":"盟科药业-U06月20日遭主力抛售306.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544142970","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544142970?lang=zh_cn&edition=full","pubTime":"2025-06-20 15:20","pubTimestamp":1750404056,"startTime":"0","endTime":"0","summary":"06月20日, 盟科药业-U股价跌0.82%，报收6.06元，成交金额4899.2万元，换手率2.19%，振幅3.11%，量比0.56。盟科药业-U今日主力资金净流出306.1万元，连续6日净流出，上一交易日主力净流出389.3万元。该股近5个交易日下跌9.96%，主力资金累计净流出3461.2万元；近20日主力资金累计净流出7951.6万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620170011a7142b3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620170011a7142b3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2544920935","title":"盟科药业-U06月18日遭主力抛售598.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544920935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544920935?lang=zh_cn&edition=full","pubTime":"2025-06-18 15:22","pubTimestamp":1750231325,"startTime":"0","endTime":"0","summary":"06月18日, 盟科药业-U股价跌2.04%，报收6.25元，成交金额7098.0万元，换手率3.09%，振幅3.45%，量比0.66。盟科药业-U今日主力资金净流出598.9万元，连续4日净流出，上一交易日主力净流出1659.6万元。该股近5个交易日下跌8.09%，主力资金累计净流出2449.3万元；近20日主力资金累计净流出5530.6万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618172430a4b03cdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618172430a4b03cdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688373"],"gpt_icon":0},{"id":"2543627956","title":"盟科药业-U06月16日遭主力抛售507.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543627956","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543627956?lang=zh_cn&edition=full","pubTime":"2025-06-16 15:21","pubTimestamp":1750058486,"startTime":"0","endTime":"0","summary":"06月16日, 盟科药业-U股价跌0.15%，报收6.72元，成交金额9080.5万元，换手率3.67%，振幅4.01%，量比0.53。盟科药业-U今日主力资金净流出507.3万元，上一交易日主力净流出1267.5万元。该股近5个交易日下跌2.33%，主力资金累计净流入146.7万元；近20日主力资金累计净流出6809.1万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616171709a4abba31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250616171709a4abba31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0},{"id":"2543577080","title":"盟科药业-U大跌5% 近半年2家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2543577080","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543577080?lang=zh_cn&edition=full","pubTime":"2025-06-13 14:43","pubTimestamp":1749797001,"startTime":"0","endTime":"0","summary":"06月13日，盟科药业-U股价大幅下跌，截至14点43分，盟科药业-U下跌5.11%，报6.69元/股，成交1.25亿元，换手率4.98%。此外，数据统计显示，近半年内2家券商给予买入建议。资金动向截止发稿，盟科药业-U获得主力净流出1126万元，其中超大单流出775万元，大单流出350万元。融资融券方面，盟科药业-U06月11日获得融资净买入566万元，当日该股融资余额为6662万元，当较前一日增加9.30%，实现2连增。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613144343951aa60e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613144343951aa60e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688373","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753424352533,"stockEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":0.2196},{"period":"3month","weight":0.2931},{"period":"6month","weight":0.671},{"period":"1year","weight":0.7427},{"period":"ytd","weight":0.5628}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.0943},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.2425},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12645人(较上一季度增加0.98%)","perCapita":"28947股","listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","registeredCapital":"65560万元","survey":"　　上海盟科药业股份有限公司的主营业务是小分子化药研发。公司的主要产品是MRX-1康替唑胺片、MRX-4康替唑胺片、MRX-8康替唑胺片、MRX-5康替唑胺片。","listedPrice":8.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业,688373,盟科药业股票,盟科药业股票老虎,盟科药业股票老虎国际,盟科药业行情,盟科药业股票行情,盟科药业股价,盟科药业股市,盟科药业股票价格,盟科药业股票交易,盟科药业股票购买,盟科药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}